MedPath

Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure

Terminated
Conditions
Patent Ductus Arteriosus
Interventions
Device: near infrared spectroscopy
Registration Number
NCT03026192
Lead Sponsor
Albany Medical College
Brief Summary

Using cerebral and renal near infrared spectroscopy monitoring to determine PDA closure in preterm infants after completing medical treatment for a hemodynamically significant PDA.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
4
Inclusion Criteria
  • preterm infants less than 32 weeks gestation
Exclusion Criteria
  • infection, congenital heart disease, syndromic anomalies, and perinatal asphyxia.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
no PDAnear infrared spectroscopyThese are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
hsPDAnear infrared spectroscopyThese are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
Primary Outcome Measures
NameTimeMethod
Change in NIRS readings3 days
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Albany Medical Center Neonatal Intesive Care Unit

🇺🇸

Albany, New York, United States

© Copyright 2025. All Rights Reserved by MedPath